Drug Free Australia series – Media suppression of alarming cannabis harms

Episode 6 – Cannabis and driving



Cannabis boom

• Medicinal cannabis – 1 million prescriptions in Oz

MINEWS

A SAR PARTY MARCHES

Just In Watch Live Voice Referendum Politics World Business Analysis Sport Science Health Arts Fact Check Coronavirus Oth

ANDLINE

VIDEO: Cannabis Boom: Australians embrace pharmaceutical cannabis

Sean Murphy Posted Sun 27 Aug 2023 at 12:55pm, updated Sun 27 Aug 2023 at 4:10pm



There's a boom in the use of pharmaceutical cannabis in Australia. More than a million prescriptions have been filled since medic cannabis was legalised in 2016 (Sean Murphy)

https://www.abc.net.au/news/rural/programs/landline/2023-08-27/cannabis-boom:-australians-embrace-pharmaceutical/102782024

1. Hater tange

The science

Placebo response very high in cannabis studies

"The unusually high attention and engagement linked to cannabinoid pain trials was independent of the clinical results and may uphold high expectations and placebo responses in future trials. In particular, we found that news articles and blogs had a strong positive bias toward the efficacy of cannabinoids in pain therapy. The positive media attention on cannabinoids for pain relief could partly explain the placebo responses seen in this systematic review."

Placebo Response and Media Attention in Randomized Clinical Trials Assessing Cannabis-Based Therapies for Pain A Systematic Review and Meta-analysis

Filip Gedin, PhD, Sebastian Blomé, MSc, Moa Pontén, PhD: Maria Lakouni, PhD: Jens Fust, PhD, Andreé Raquette, DC, Viktor Vadermark Lundquist, MSc, William H, Thompson, PhD, Karin Jensen, PhD

bstract

ORTANCE: Presistent pain is a common and disabiling health problem that is often difficult to . There is an increasing interest in medicinal cannabis for treatment of persistent pain, however inited superiority of cannabinodis over placebo in clinical trials suggests that positive catalons may contribute to the improvements. ints n What is the size

t to placebo response in cana for clinical pain, and is the placebo response associat attention on the trials?

f pain and to correlate these responses studies of M3 significant puplacebo in ca d within the MEDLINE and Embase clinical trials.

SELECTION Cannabinoid studies with a double blind, placebo-controlled design with ants IB years or older with clinical pain of any duration were included. Studies were excluded reated individuals with HIV/AIDS or severe skin disorders.

TA EXTRACTION AND SYNTHESS: The study followed the Preferred Important guiness for lemnatic Review and Meta analysiss reporting guideline. Data were extracted by independent evens: Quality assessment was performed using the Biok of Unia: Jook. Altention and emination metrics for each trial were estimated with Mineteric and Crosserf. Data were pooled analysed using a random effects statistics model.

Supplemental content Author affiliations and article infor

Author affiliations and article infor listed at the end of this article.

ESULTS "twenty studies, including 14-99 includuals (innear [SD] age, S1 (7) years, age range, 33-62, ans, 85 Smaller (55%), were included. Plan interprive as accorded with a significant reduction in power to justice, but includes in a moderate to large which is the main S15 and page. G4 (501), P < 0.05, the amount media attention and desimation from the dise schemation S11 and page. G4 (501), P < 0.05, the amount media attention and desimation limits of use and that was proportionally high, with a strong stiller black, but was not associated with the disical outcomes.

DNCLUSIONS AND RELEVANCE Placebo contributes significantly to pain reduction seen in mnationoid clinical trials. The positive media attention and wide dissemination may uphold hig pectations and shape placebo responses in future trials, which has the potential to affect the

Minuncip

https://jamanetwork.com/journals/jamanetworkopen/ fullarticle/2799017

Affects work

Employers concerned about cannabis intoxication



to keep their jobs Some workers have been stood down while others face stigma or are hiding their use. But reform could be on the way Get our morning and afternoon news emails, free app or

 Adeeshola Ore

 sat 26 Aug 2023 10.00 AEST

 f

daily news podcast



https://www.theguardian.com/society/2023/aug/26/this-is-a-medicinethe-australians-prescribed-cannabis-but-left-fighting-to-keep-their-jobs

- the Number

Affects driving

Cannabis lobby seeking legislative change to allow driving for medicinal cannabis patients

MINEWS

A SAR PARTY MARCHES

ABC RURAL

Chronic illness sufferers push for reform of cannabis driving laws lagging behind the science

Landline / By Sean Murphy Posted Sat 26 Aug 2023 at 8:58a



https://www.abc.net.au/news/rural/2023-08-26/chronic-illness sufferers-push-for-cannabis-driving-reform/102756426


- Bally Mana

Claim

Lobbyists claim that studies showing intoxicated cannabis users causing more road deaths are wrong

• This Parliamentary submission states:


"Crash Risk. Epidemiological studies show that the presence of THC in blood is associated with a modest increase in the risk of being involved in any crash (crash risk), and in being responsible for that crash (culpability risk). The elevation in risk is modest (odds ratio [OR]: 1.1–1.4) when a range of potentially confounding factors are controlled for (e.g., the presence of other drugs, the fact that recreational cannabis users are likely to be younger and more prone to risky behaviour). The overall increase in risk in is considerably less than that seen with other prescription drugs for which driving is legal in patients (e.g. opioids (ORs: 1.7–2.3), benzodiazepines (ORs: 1.2–2.3)) and a 0.05% blood alcohol concentration (BAC) (ORs: 1.4-1.8)."




https://www.parliament.nsw.gov.au/lcdocs/submissions/78665/070%20 Lambert%20Initiative%20for%20Cannabinoid%20Therapeutics.pdf


Hotheads?

Three graphs from Colarado's cannabis legalisation






Percent of All TRAFFIC DEATHS where Driver Tested Positive for Cannabis



2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019





https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8672945/

Fact

62% of Australians in 2020 using cannabis for 'chronic pain' (CBD does not need prescription)

- another 12% for other pain conditions migraines etc
- so 3 in every 4 patients using cannabis for pain

Application Date	Status	Decision Date		Consulting Locations. State or Territory			
						Patient Gender	Previous SAS Number
10/5/2020	Approved	11/5/2020	Achalasia	VIC	Schedule 4	Male	No
17/4/2020	Approved	17/4/2020	Achalasia	QLD	Schedule 4	Male	No
16/1/2020	Approved	16/1/2020	Achalasia	QLD	Schedule 4	Female	No
6/1/2020	Approved	6/1/2020	Achalasia	SA	Schedule 4	Female	No
20/12/2019	Approved	23/12/2019	Achalasia	VIC	Schedule 4	Male	Yes
5/12/2019	Approved	5/12/2019	Achalasia	VIC	Schedule 4	Male	No
20/9/2019	Approved	20/9/2019	Achalasia	NSW	Schedule 4	Male	No
22/3/2020	Approved	23/3/2020	AD - Alzheimer's disease	VIC	Schedule 4	Male	No
7/3/2020	Approved	10/3/2020	AD - Alzheimer's disease	VIC	Schedule 4	Female	No
2/12/2019	Approved	3/12/2019	AD - Alzheimer's disease	VIC	Schedule 4	Female	Yes
10/11/2019	Approved	12/11/2019	AD - Alzheimer's disease	VIC	Schedule 4	Female	Yes
8/11/2019	Approved	8/11/2019	AD - Alzheimer's disease	VIC	Schedule 4	Female	No
25/10/2019	Approved	25/10/2019	AD - Alzheimer's disease	VIC	Schedule 4	Female	No
11/10/2019	Approved	11/10/2019	AD - Alzheimer's disease	VIC	Schedule 4	Female	Yes
29/9/2020	Approved	30/9/2020	ADHD - Attention deficit disorder with hyperactivity	QLD	Schedule 8	Male	No
29/9/2020	Approved	30/9/2020	ADHD - Attention deficit disorder with hyperactivity	QLD	Schedule 8	Male	Yes
28/9/2020	Approved	29/9/2020	ADHD - Attention deficit disorder with hyperactivity	QLD	Schedule 8	Male	No
24/9/2020	Approved	28/9/2020	ADHD - Attention deficit disorder with hyperactivity	QLD	Schedule 8	Male	No
23/9/2020	Approved	24/9/2020	ADHD - Attention deficit disorder with hyperactivity	VIC	Schedule 8	Male	No
22/9/2020	Approved	24/9/2020	ADHD - Attention deficit disorder with hyperactivity	QLD	Schedule 8	Male	No
22/9/2020	Approved	24/9/2020	ADHD - Attention deficit disorder with hyperactivity	QLD	Schedule 8	Male	No
22/9/2020	Approved	24/9/2020	ADHD - Attention deficit disorder with hyperactivity	QLD	Schedule 8	Male	Yes
22/9/2020	Approved	24/9/2020	ADHD - Attention deficit disorder with hyperactivity	VIC	Schedule 8	Male	No
21/9/2020	Approved	22/9/2020	ADHD - Attention deficit disorder with hyperactivity	NSW	Schedule 8	Male	No
18/9/2020	Approved	22/9/2020	ADHD - Attention deficit disorder with hyperactivity	QLD	Schedule 8	Male	No
15/9/2020	Approved	16/9/2020	ADHD - Attention deficit disorder with hyperactivity	QLD	Schedule 8	Male	No
14/9/2020	Approved	15/9/2020	ADHD - Attention deficit disorder with hyperactivity	QLD	Schedule 4	Male	No
14/9/2020	Approved	15/9/2020	ADHD - Attention deficit disorder with hyperactivity	QLD	Schedule 4	Male	No
14/9/2020	Approved	16/9/2020	ADHD - Attention deficit disorder with hyperactivity	QLD	Schedule 8	Male	No
10/9/2020	Approved	11/9/2020	ADHD - Attention deficit disorder with hyperactivity	QLD	Schedule 4	Male	No
9/9/2020	Approved	10/9/2020	ADHD - Attention deficit disorder with hyperactivity	VIC	Schedule 8	Female	No

Australian prescriptions

·福祉行社社

The science

• Cannabis and alcohol have an additive effect

"Cannabis-alcohol SDLP (lane weaving) effects were additive rather than synergistic, with 5µg/L THC+0.05g/210L alcohol showing similar SDLP to 0.08g/210L alcohol alone. Only alcohol increased lateral acceleration and the less-sensitive lane departures/min parameters. OF effectively documented cannabis exposure, although with greater THC concentration variability than paired blood samples." Publiced®
Advanced

Save Email

Controlled Clinical Trial > Drug Alcohol Depend. 2015 Sep 1:154:25-37.
doi: 10.1016/j.drugalcdep.2015.06.015. Epub 2015 Jun 23.

Compacision of effocts on one deviation between laconstral with and

Cannabis effects on driving lateral control with and without alcohol

Rebecca L Hartman ¹¹, Timothy L Brown ², Gary Milavetz ³, Andrew Spurgin ³, Russell S Pierce ⁴, David A Gorelick ⁶, Gary Gaffney ⁶, Marilyn A Huestis ⁷

> s + expand 44593 PMCID: PMC4536116 DOI: 10.10

PMID: 26144593 PMCID: PMC4536116 DOI: 10.1016/j.drugalcdep.2015.06.015 Free PMC article

Abstra

Background: Effects of cannabis, the most commonly encountered non-alcohol drug in driving under the influence cases, are heavily debated. We aim to determine how blood $\Delta\beta$ tetrahydrocannabinol (THC) concentrations relate to driving impairment, with and without alcohol.

Methods: Current occasional (c1-/last 2 months, 53day;/week) cannabis mokers drank placebo or low-dose alcohol, and inhaled 500mg placebo, low (2.9%)-IT4C, or high (6.7%)-IT4C vaporized cannabis over 10min ad libitum in separate sessions (within-subject design, (conditions). Participants drove [National Advanced Driving Simulator, University of lowa) simulated drives (-0.8h duration). Bodo, and Tirdi (OP), and breath alcohol samples were collected before (0.17%, 0.42h) and after (1.4h, 2.3h) driving that occurred 0.5-1.3h after inhalation. We evaluated standard deviations of lateral position (lane weave, SDLP) and stering angle, lane departure/min, and maximum lateral acceleration.

Results: In N=16 completers (13 men, ages 21-37)eard), cannabis and alcohol increased SDU Blood THC concentrations of A2 and 13.1µg/L during driving increased SDUP similar to 0.05 and 0.08g/210L breath alcohol concentrations, the most common legal alcohol limits. Cannabis-alcohol SDLP effects were additive rather than synergistic, with 5µg/L THC-0.05g/21C lacohol showing similar SDLP to 0.08g/21C lacohol alone. Only alcohol increased lateral acceleration and the less-sensitive lane departures/min parameters. OF effectively documented cannabis exposure, although with greater THC concentration variability than paired blood samples.

https://pubmed.ncbi.nlm.nih.gov/26144593/

The science


• Cannabis and other drugs – synergistic effect

The Dangers of Mixing Marijuana and Opioids

Research has shown that the combination of marijuana and opioids can be therapeutic to some people suffering from chronic pain. In one study, individuals who smoked marijuana while being administered small doses of oxycodone experienced enhanced pain threshold and tolerance compared to the effects of taking oxycodone alone.⁵

The synergistic effects obtained by combining these drugs can be very beneficial to patients as it would allow lower doses of opioids to provide pain relief, reducing the likelihood of prescription opioid addiction and overdoses.

However, marijuana and opioids both have depressant effects, and when combined at nonmedical doses these drugs can suppress the central nervous system to dangerous levels.⁶ This can result in decreased brain function, low blood pressure, extreme sedation, coma, and death.



The Dangers of Mixing Marijuana and Opioids

Research has shown that the combination of marijuana and opiolds can be therapeutic to some people suffering from chronic pain. In one study, individuals who smoked marijuana while being administered small doses of oxycodone experienced enhanced pain threshold and tolerance compared to the effects of taking oxycodone alone.⁵

The synergistic effects obtained by combining these drugs can be very beneficial to patients as would allow lower doses of opioids to provide pain relief, reducing the likelihood of prescription opioid addiction and overdoses.

However, marijuana and opioids both have depressant effects, and when combined at nonmedical doses these drugs can suppress the central nervous system to dangerous levels.[®] This can result in decreased brain function, low blood pressure, extreme sedation, coma, and death.

Unfortunately, the combination of marijuana and opiolds among recreational users is a common occurrence. One study found that 7 out of 10 teens who take prescription opiologs for nonmedical reasons combine them with other drugs or alcohol, with marijuana being the most commonly coingested substance.⁷

Studies have shown that the use of marijuana increases the abuse potential for opioids as well as other undesirable side effects, Analysis of data from the National Epidemiologic Survey on Alcohol and Related Conditions suggests that marijuane users are more than two and a half times more likely to misuse prescription opioids and develop prescription opioid use disorder compared to nonusers.⁸

<u>A recent study</u> published in the *Journal of Addiction Medicine* also showed that combined use of oploid and marijuana was linked to greater symptoms of anxiety, depression, and substance use problems.⁹

https://americanaddictioncenters.org/marijuana-rehab/mixingweed-opioids

Conclusion

- Lobbyists want medical cannabis users to legally drive
 - 3 in every 4 medical cannabis users treat pain
 - 62% use it for chronic pain
 - because cannabis does little for chronic pain, they will need to be using cannabis with other drugs like opiates
 - the synergistic effects of cannabis and opiates is incompatible with driving safety
 - and this is true for the majority of Australians using medical cannabis



Next episode

More detail in future episodes:

the states

• Cannabis and cancer

- Cannabis and birth defects
- Cannabidiol (CBD), cancer and birth defects
- Cannabis and pain
- Cannabis and driving
- Hemp and psychoactive metabolites
- Cannabis and psychosis
- Cannabis and violence/homicide
- Cannabis and suicide
- Cannabis its other harms